Novartis' Jimenez gives biosimilar update

At the JPMorgan Healthcare Conference on Monday, Novartis AG (NYSE:NVS; SIX:NOVN) CEO Joe Jimenez outlined the pharma's commercial strategy for new and upcoming biosimilars, and discussed the company's expectations of price erosion

Read the full 329 word article

User Sign In